Edward Pershing - 09 Feb 2026 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role: CEO, Director
Signature: /s/ Edward Pershing
Issuer symbol: PVCT
Transactions as of: 09 Feb 2026
Net transactions value: +$99,998
Form type: 4
Filing time: 11 Feb 2026, 18:24:20 UTC
Previous filing: 09 Feb 2026
Next filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pershing Edward	CEO, Director	800 S. GAY STREET,, SUITE 1610, KNOXVILLE	/s/ Edward Pershing	11 Feb 2026	0001689739

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PVCT	Series D-1 Convertible Preferred Stock	Purchase	$99,998	+34,940	+1.4%	$2.86^*	2,613,807	09 Feb 2026	Common Stock	349,400		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person acquired 34,940 shares of Series D-1 Preferred Stock in a private transaction.
F2	Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F3	The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.